Five things for pharma marketers to know: Wednesday, October 19, 2016


1. The FDA approved Roche's immunotherapy Tecentriq for the treatment of non-small cell lung cancer, making it a new competitor against Bristol-Myers Squibb's Opdivo and Merck's Keytruda. According to study results, patients taking Tecentriq lived on average 4.2 months longer than those on chemotherapy. (Reuters)

2. Harvard Law School's Center for Health Law and Policy Innovation filed complaints alleging that seven insurers in eight states have discriminated against HIV patients by making drugs need by HIV/AIDs patients unavailable or unaffordable. (NPR)

3. The FDA proposed pulling the approvals of two generic alternatives to Johnson & Johnson's Concerta, an ADHD drug. The agency is concerned that patients have reported that the generic pills are less effective than Concerta. (Regulatory Focus)

4. The Centers for Disease Control and Prevention and other cancer organizations are urging healthcare providers to promote the human papillomavirus vaccine for its cancer-fighting benefits instead of protection against sexually transmitted infections. (WSJ)

5. Instagram launched a series of suicide prevention tools, allowing users to report friends' troubling posts anonymously and offering support options such as talking to a friend, contacting a helpline, and receiving tips. The social media app collaborated with the National Eating Disorders Association and the National Suicide Prevention Lifeline to create appropriate language. (Engadget)